VIRUSES vs. SUPERBUGS
The book and the author Book reviews Blog
 and news Commented links
  1. •Phage therapy literature
Any
questions? Buy
the book Book excerpt What is it 
all about? Home
 
  1. Phage therapy literature
  2.  
  3. Phage therapy has a rich history. The first paper that has to do with it was published in 1896.
  4. On this page you can find the literature of the field I was able to track down. The list will be updated when new references come in. Last update: November 2007
  5. I appreciate hints for references I missed: thaeusler at vtxmail.ch
  1. •Abdul-Hassan, H.S. et al. (1990) ‘Bacteriophage therapy of pseudomonas burn wound sepsis‘ Ann Mediterr Burn Club 4:262-264
  2. •Ackermann, H.-W. (2001) ‘The rise of bacteriophages‘ Virol 5:35-43
  3. •Adamia, R. et al: (1990) ‘The virulent bacteriophage IRA of Salmonella typhimurium: cloning of phage genes that are potentially lethal for the host cell‘ J Basic Microbiol 30:707-716
  4. •Adhya, S. et al. (2005) ‘2004 ASM Conference on the New Phage Biology: the 'Phage Summit'‘ Mol Microbiol 55:1300-14
  5. •Ahmad, S. I. (2002) ‘Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics‘ Med Hypotheses 58:327-31
  6. •Akimkin, V.G. et al. (1998) ‘Ispol'zovanie adaptirovannogo sal'monelleznogo bakteriofaga v praktike lecheniia i profilaktiki nozokomial'nogo sal'monelleza‘ [‘Practical use of adapted Salmonella bacteriophage for the treatment and prevention of nosocomial infections‘]. Zhurn Mikrobiol Epidem Immunobiol 85-86
  7. •Alisky, J. et al. (1998) ‘Bacteriophages show promise as antimicrobial agents‘ J Infect 36:5-15
  8. •Anonymus (1930) ‘Bacteriophage therapy‘ Ind Med Gaz 65:91
  9. •Anonymus (1931) ‘Limitations of Bacteriophage Therapy‘ JAMA 96: 693
  10. •Anonymus (1932) ‘Further limitations of Bacteriophage Therapy‘ JAMA 98:1190
  11. •Anonymus (1933) Editorial 100:1431-1432
  12. •Anonymus (1933) Editorial JAMA 100:1603-1604
  13. •Anonymus (2006) [‘Ambivalent bacteriophages of different species active on Escherichia coli K12 and Salmonella sps. strains‘] Genetika 42:159-68
  14. •Asheshov, I. (1922) Compt Rend Soc Biol 87:168
  15. •Asheshov, I. et. al. (1931) ‘The treatment of cholera with bacteriaphage‘ Ind med Gaz 66:179
  16. •Asheshov, I. et. al. (1937) Lancet 1:319-320
  17. •Atterbury, R. J. et al. (2007) ‘Bacteriophage therapy to reduce salmonella colonization of broiler chickens‘ Appl Environ Microbiol 73:4543-9
  18. •Babsky, E. B. et al. (eds) Microbiology and Epidemiology – Achievements of Soviet Medicine in the Patriotic War, Medical Publications (English edition)
  19. •Barrow, P.A. and Soothill, J.S. (1997) ‘Bacteriophage Therapy and Prophylaxis: rediscovery and renewed assessment of the potential‘ Trends Microbiol 5:268-271
  20. •Barrow, P.A. et al. (1998) ‘Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves‘ Clin Diag Lab Immunol 5:294-298
  21. •Beckerich, A., Hauduroy, P. (1922) ‘Le bactériophage dans le traitment de la fièvre typhoïde‘ Compt Rend Soc Biol 86:168
  22. •Belikov, P.E. (1947) ‘The fight against intestinal infections‘ Am Rev Sov Med 4:238-42
  23. •Berchieri, A. et al. (1991) ‘The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium‘ Res Microbiol 142:541-549
  24. •Bertoye et. al. (1959) ‘Les bacteriophages adaptes dans le traitement des infections a germes resistant aux antibiotiques‘ J Med Lyon 20. Mai:465-471
  25. •Bertschinger, J.P. (1957) ‘Le bactériophage’ Schw Apothekenzeit 95:479–87
  26. •Biswas, B. et al. (2002) ‘Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium‘ Infect Immun 70:204-10
  27. •Blahova, J. et al. (2001) ‘Bacteriophages transducing antibiotic resistance from a cluster of lysogenic strains of Pseudomonas aeruginosa isolated from patients‘ J Chemother 13:331-333
  28. •Bock, E (1939) ‘Zur Anwendung von Bakteriophagen in der Therapie bei der Wehrmacht‘ Dtsch Mil-Arzt 4:273
  29. •Bogovazova, G.G. et al. (1991) [The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection]. [Russian]. Zhurn Mikrobiol, Epidem i Immunobiol 4:5-8
  30. •Bogovazova, G.G. et. al. (1992). [Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages]. [Russian]. Zhurn Mikrobiol, Epidem i Immunobiol 30-33.
  31. •Boratinski, J. et al. (2004) ‘Preparation of endotoxin-free bacteriophages‘ Cell Mol Biol Lett 9:253-9
  32. •Bordet, J. et Ciuca, M. (1920) ‘Excsudats leucocytaires et autolyses microbiennes transmissible‘ Compt Rend Soc Biol 83:1296
  33. •Bordet, J. et Ciuca, M. (1920) ‘Le bacteriophage de d’Herelle, sa production et son interpretation‘ Compt rend Soc Biol 83:1296
  34. •Bordet, J. et Ciuca, M. (1921) ‘Autolyse microbienne et serum antilytique‘ Compt Rend Soc Biol 84:280
  35. •Bordet, J. et Ciuca, M. (1921) ‘Determinisme de l’autolyse microbienne transmissible‘ Compt Rend Soc Biol 84:276
  36. •Bordet, J. et Ciuca, M. (1921) ‘Evolution des cultures de coli lysogene‘ Compt Rend Soc Biol 84:747
  37. •Bordet, J. et Ciuca, M. (1921) ‘Guerison et retour a l’etat primitif, par le serum antilytique, du coli lysogene‘ Compt Rend Soc Biol 84:748
  38. •Bordet, J. et Ciuca, M. (1921) ‘Remarques sur l’histoire des recherches, concernant la lyse microbienne transmissible‘ Compt Rend Soc Biol 84:745
  39. •Bordet, J. et Ciuca, M. (1921) ‘Spécificité de l’autolyse microbienne transmissible‘ Compt Rend Soc Biol 84:278
  40. •Bordet, J. (1921) ‘Discussion on the bacteriophage‘ BMJ, 2:289-297
  41. •Bordet, J. (1924) ‘La théorie de l’autolyse transmissible et les objections de d‘Herelle‘ Compt Rend Soc Biol 90:96-8
  42. •Bordet, J. (1925) ‘La théorie de l’autolyse transmissible et les objections de d‘Herelle‘ Compt Rend Soc Biol 93:1432
  43. •Bordet, J. (1925) ‘Pouvoir lysogene actif ou spontane et pouvoir lysogene passif ou provoqué‘ Compt rend Soc Biol 93:1054
  44. •Bordet, J. (1926) ‘A propos de la note ci-dessus de d‘Herelle‘ Compt Rend Soc Biol 94:975
  45. •Bordet, J. (1931) ‘Croonian Lecture-The theories of bacteriophage‘ Proc Roy Soc London Ser B 107:398-417
  46. •Bower, AG (1938) ‘Modern treatment of typhoid fever‘ Mil Surgeon 83:70
  47. •Boyd, J.S.K. and Portnoy, B. (1944) ‘Bacteriophage therapy in bacillary dysentery‘ Trans Roy Soc Trop Med Hyg 37:243-262
  48. •Bronfenbrenner, J.J. and Sulkin, E. (1939) ‘Bacteriophage therapy. II. Prophylactic and therapeutic effect of bacteriophage and of antivirus in experimental infections of the eye‘ J Infect Dis 65:58
  49. •Bronfenbrenner, J.J. and Sulkin, E. (1939) ‘Bacteriophage therapy. III. On the nature of the deleterious effect of the local application of staphylococcus bacteriophage‘ J Infect Dis 65:64-72
  50. •Broxmeyer, L. et al. (2002) ‘Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage Delivered by a Nonvirulent Mycobacterium: A Model for Phage Therapy of Intracellular Bacterial Pathogens‘J Infect Dis 186:1155-60
  51. •Brüssow, H. (2005) ‘Phage therapy: the Escherichia coli experience‘ Microbiol 151:2133-40
  52. •Bruttin, A. and Brüssow, H. (2005) ‘Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy‘ Antimicrob Agents Chemother 49:2874-8
  53. •Bruynoghe, R. and J. Maisin (1921) ‘Essais de therapeutique au moyen du bacteriophage du staphylocoque‘ C R Soc Biol 85:1120-1121
  54. •Bruynoghe, R. and Maisin, J. (1921) ‘Essais de therapeutique au moyen du bacteriophage du staphylocoque‘ C R Soc Biol 85:1118
  55. •Bruynoghe, R. and Maisin, J. (1921) ‘Essais de therapeutique au moyen du bacteriophage du staphylocoque‘ C R Soc Biol 85:1122
  56. •Bryant, R.E. et al. (1965) ‘Treatment of recurrent furunculosis with staphylococcal bacteriophage-lysed vaccine‘ JAMA 194:11-14
  57. •Bull, J.J. et al. (2002) ‘Dynamics of success and failure in phage and antibiotic therapy in experimental infections‘ BMC Microbiol 2:35
  58. •Burckhardt (1944) ‘Placentadurchlässigkeit für Phagen‘ Ph.D. Thesis Univ. of Basel
  59. •Burnet, F. and McKie, M. (1929) ‘Observations on a permanently lysogenic strain of B. enteridis gaerther‘ Austral J Exptl Biol Med Sci 6:277-284
  60. •Burnet, F.M. (1930) ‘Bacteriophage and cognate phenomena‘ in A System of bacteriology, Vol. 7, London, pp. 463-509
  61. •Burnet, F.M. et al. (1930) ‘Investigations on bacilliary dysentery in infants, with special reference to the bacteriophage phenomena‘ Med J Austral 2:71-78
  62. •Burnet, F.M. (1934). ‘The bacteriophages‘ Biol Rev Cambridge Phil Soc 9:332-350
  63. •Caldwell, J. (1928) ‘Bacteriologic and bacteriophagic study of infected urines‘ J Infect Dis 39:343-362
  64. •Cao, J. et al. (2000) ‘Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth‘  Biochim Biophys Acta 1474:107-113
  65. •Capparelli, R. et al. (2007) ‘Experimental Phage Therapy against Staphylococcus aureus in Mice.‘ Antimicrob Agents Chemother 2007 518:2765-73
  66. •Carlton, R.M. (1999) ‘Phage therapy: past history and future prospects‘ Arch Immunol Ther Exp 47:267-274
  67. •Carrera, M.R. et al. (2004) ‘Treating cocaine addiction with viruses‘ PNAS 101:10416-10421
  68. •Cerveny, K.E. et al. (2002) ‘Phage Therapy of Local and Systemic Disease Caused by Vibrio vulnificus in Iron-Dextran-Treated Mice‘ Infect Immun 70:6251-62
  69. •Chang, H.-C. et al. (2005) ‘Isolation and Characterization of Novel Giant Stenotrophomonas maltophilia Phage {phi}SMA5‘ Appl Environ Microbiol 71:1387-93
  70. •Chanishvili, N. et al. (2001) ‘Phages and their application against drug resistant bacteria’ J Chem Technol Biotechnol 76:1–11
  71. •Cheng, Q. et al. (2005) ‘Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage, lytic enzyme‘ Antimicrob Agent Chemother 49:111-117
  72. •Cherwonogrodzky, J.W. (2005) ‘Research strategies for the treatment of biothreats‘ Curr Opin Pharmacol 5:465-72
  73. •Chibani-Chennoufi, S. et al. (2004) ‘Isolation of Escherichia coli bacteriophages from the stool of paediatric diarrhoea patients in Bangladesh’, J Bact 186:8287–94
  74. •Chibani-Chennoufi, S. et al. (2004) ‘In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli phages: Implications for Phage Therapy‘ Antimicrob Agents Chemother 48:2558-69
  75. •Choudhury and Morison, J. (1929) ‘The spread of dysentery in a khasi village and its treatment with bacteriophage‘ Ind Med Gaz 64
  76. •Cislo, M. et al. (1987) ‘Bacteriophage treatment of suppurative skin infections‘ Arch Immunolog Therap Exp (Warsz) 35:175-183
  77. •Ciuca, M. (1923) ‘Présence de principe lytique pour le bacille de Shiga et le colibacille dans les selles des choleriques‘ Compt Rend Soc Biol 88:143
  78. •Clajus, W. (1959) ‘Die therapeutische Anwendung von Bakteriophagen unter besonderer Berücksichtigung des Typhus and Paratypus‘ Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt 1 Ref 170:427-495
  79. •Clark, P.F. and Schiedt, C.A. (1927) ‘A bacteriophage active against a virulent hemolytic streptococcus‘ Proc Soc Exp Biol 24: 635-639
  80. •Clauberg, K.W. (1944) ‘Therapeutische und prophylaktische Massnahmen bei Typhus- Paratyphus- und Diphterie-Bazillenausscheidern‘ Thp Gegenw 85:58
  81. •Coleman, D.C. et al. (1989) ‘Staphylococcus aureus bacteriophages mediating the simultaneous lysogenic conversion of beta-lysin, staphylokinase and enterotoxin A: Molecular mechanism of triple conversion‘ J Gen Micr 135: 1679-1697
  82. •Compton, A. (1942) ‘Phage therapy in diarrhoea and dysentery‘ BMJ I:719-720
  83. •Compton, A. (1944) ‘Results of bacteriophage treatment of bacillary dysentery at Alexandria A statistical retrospect‘ Lancet v2:192-193
  84. •Compton, A. (1949) ‘Felix d’Herelle (Obituary)‘ Nature 163:984-985
  85. •Corbel, M.J. and Morris, J.A. (1980) ‘Investigation of the effect of Brucella-phage on the course of experimental infection with Brucella abortus‘ Brit Vet J 136:278-289
  86. •Couvy, L. und Popoff (1931) ‘Essai de traitement de la peste par le bacteriophage‘ Presse med 36:817
  87. •D‘Herelle, F. (1916) ‘Sur un bacille dysenterique atypique‘ Ann Inst Pasteur 30:145-7
  88. •D‘Herelle, F. (1917). ‘Sur un microbe invisible antagoniste des bacteries dysentèriques‘ Compt Rend Acad Sci Paris 165:373
  89. •D‘Herelle (1920) ‘Sur le microbe Bacteriophage. Compt rend Soc Biol 83:247
  90. •D’Herelle, F. (1920) ‘Phénomènes coincidant avec l’aquisition de la resistance des bacteries a l’action du bacteriophage‘ Compt Rend Soc Biol 83:384
  91. •D’Herelle, F. (1920) ‘Sur la résistance des bacteries à l’action du microbe  Bacteriophage‘ Compt rend Soc Biol. 83:97
  92. •D’Herelle, F. (1920) ‘Sur le microbe bacteriophage‘ Compt rend Soc Biol 83:1318
  93. •D’Herelle, F. (1920) Sur la nature du  Bacteriophage‘ Compt rend Soc Biol 83:339
  94. •D’Herelle, F. and Eliava, G. (1921) ‘Sur le serum anti-bacteriophage‘ Compt Rend Soc Biol 84:719
  95. •D’Herelle, F. (1921) ‘Le microbe bactériophage, agent d'immunité dans la peste et la barbone‘ C R Acad Sci Ser D 172:99
  96. •D’Herelle, F. (1921) Le bactériophage: son rôle dans l'immunité, Masson
  97. •D‘Herelle, F. (1921) ‘Le bactériophage: Son rôle dans l'immunité‘ Presse méd 29:463
  98. •D‘Herelle, F. (1922) The Bacteriophage: Its Role in Immunity Williams and Wickens Co./Waverly Press
  99. •D‘Herelle, F. et al. (1922) ‘Discussion on the Bacteriophage (Bacteriolysin) from the Ninetieth Annual Meeting of the British Medical Association, Glasgow, July, 1922‘ BMJ 2:289-297
  100. •D’Herelle, F. (1923) ‘Sur l’autonomie du bacteriophage‘ Compt Rend Soc Biol 87:25
  101. •D’Herelle, F. (1923) ‘Sur l’etat physique du bacteriophage‘ Compt Rend Soc Biol 87:27
  102. •D’Herelle, F. (1923) Les défenses de l'organisme, Ernest Flammarion
  103. •D‘Herelle (1923) ‘Sur la presence du bacteriophage dans les leucocytes‘ Compt. Rend. Soc. Biol. 87:477
  104. •D’Herelle, F. (1924) Immunity in natural infections and disease, Smith D’Herelle, F. (1925) ‘Essai de traitement de la peste bubonique par le bacteriophage‘ Presse med 33:1393-94
  105. •D’Herelle, F. (1926) ‘Sur la theorie de l’autolyse transmissible de Bordet et Ciuca‘ Compt rend Soc Biol 94:973
  106. •D’Herelle, F. (1926) Le Bactériophage et son comportement, Masson et Cie
  107. •D’Herelle, F. (1928) Le Choléra asiatique, Masson
  108. •D’Herelle, F et. al (1929) ‘Studies on asiatic cholera‘ Ind Med Res Mem 14:1-161
  109. •D’Herelle, F. (1930) The bacteriophage and its behaviour, Ballier, Tindall & Cox, London/The Williams and Wilkins Company, Baltimore
  110. •D’Herelle, F. and Smith G.H. (1930) The Bacteriophage and its Clinical Application, Charles C. Thomas
  111. •D’Herelle, F. (1931) ‘Le phenomene de Twort et la bacteriophagie‘ Ann Inst Pasteur 47, 241
  112. •D’Herelle, F. (1931) ‘Le phenomene de Twort et la Bacteriophagie‘ Ann Inst Pasteur 46:618
  113. •D’Herelle (1931) ‘Le phenomene de Twort et la bacteriophagie‘ Ann Inst Pasteur 47:470-1
  114. •D’Herelle, F. (1933) Le Bactériophage et ses applications thérapeutiques, G. Doin et Cie
  115. •D’Herelle, F. (1935) Bacteriophag i fenomen vyzdorovleniya, Tbilisi National University
  116. •D’Herelle, F. (1938) Le Phénomène de la guérison dans les maladies infectieuses, Masson
  117. •D’Herelle, F. (1949) ‘Le bactériophage‘ Atomes 3:399-403
  118. •D’Herelle, F. (1949) ‘The bacteriophage‘ Science News (Penguin) 14:44-59
  119. •Da Costa Cruz, J. (1924) ‘La traitment des dysentéries bacillaires par le bactériophage‘ Compt Med Rend Soc Biol 91:845-6
  120. •Dabrowska, K. et al. (2005) ‘Bacteriophage penetration in vertebrates‘ J Appl Microbiol 98:7-13
  121. •Danelia, N. et al. (1998) ‘Bakteriophagen zur Therapie von multi-resistenten Bakterien’ Zeitschr Wundbeh 3: 16–17
  122. •Darsavelidze, M.A. et al. (2004) ‘Biological properties of bacteriophages, active to Yersinia enterocolitica‘ (Russian) Zh Mikrobiol Epidemiol Immunobiol 6:10-3
  123. •Das, P. (2001) ‘Bacteriophage therapy offers new hope for streptococcal infections‘ Lancet, 35:938
  124. •Davioud (1929) ‘Septico-pyohemie a staphylocoque doré par le bacteriophage intraveineux‘ Presse med 33:1413
  125. •Davison, W.C. (1922) ‘The bacteriolysis and therapy of bacillary dysentery  in children. Therapeutic application of bacteriolysants; d'Herelle's phenomenon‘ Am J Dis Child 23:531
  126. •Debattista, J. (2004) ‘Bacteriophage therapy: where East meets West‘ Expert Rev Anti Infect Ther 2:815-9
  127. •Delbrück, M. (1946) ‘Bacterial viruses or bacteriophages‘ Biol Rev 21:30-40
  128. •Delmastro, P. et al. (1997) ‘Immunogenicity of filamentous phage displaying peptide mimotopes after oral adminsitration‘ Vaccine 15:1276-1285
  129. •Dhayagude, R.G. and Banker D.D. ‘Treatment of typhoid fever with bacteriophage‘ Ind J med res 37:249
  130. •Dixon, B. (1984) ‘Attack of the phages‘ Science 84:66-69
  131. •Dixon, B. (1987) ‘Bacteriophage therapy‘ BMJ Clin Res Ed 294:1168
  132. •Dixon, B. (2004) ‘New dawn for phage therapy‘ Lancet Infect Dis 4:186Weld, Weld, R.J. et al. (2004) ‘Models of phage growth and their applicability to phage therapy‘ J Theor Biol 227:1-11
  133. •Djurkovic S. et al. (2005) ‘Synergistic killing of streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance‘ Antimicrob Agent Chemother 49:1225-1228
  134. •Dodd, C.E.R. et al. (2004) ‘Longitudinal Study of Campylobacter jejuni Bacteriophages and Their Hosts from Broiler Chickens‘ Appl Environ Microbiol 70:3877-83
  135. •Doermann, A.D. (1948) ‘Lysis and lysis inhibition with Escherichia coli bacteriophage‘ J Bacteriol 55:257-275
  136. •Doermann, A.D. (1952) ‘The Intracellular Growth of Bacteriophages. I. Liberation of intracellular bacteriophage T4 by premature lysis with another phage or with cyanide‘ J Gen Physiol 35:645-656
  137. •Dubos, R.J. et al. (1943). ‘The multiplication of bacteriophage in vivo and its protective effects against an experimental infection with Shigella dysenteriae‘ J Exp Med 78:161-168
  138. •Duckworth, D. (1976) ‘Who discovered bacteriophage?‘ Bact rev 40:793-802
  139. •Duerr, D.M. et al. (2004) ‘Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier‘ J Virol Methods 116:177-180
  140. •Dutta N.K. (1964) ‘Prophylaxis and treatment of cholera based on experimental evidences‘ Ind J Med Res 52:933-940
  141. •Dzuliashvili, M. et al. (2007) ‘Study of therapeutic potential of the experimental pseudomonas bacteriophage preparation.‘ Georgian Med News 147:81-88
  142. •Eaton, Monroe D. and Stanhope Bayne-Jones (1934) ‘Bacteriophage Therapy Review of the principles and results of the use of bacteriophage in the treatment of infections (I-III) ‘ JAMA 103:1769-1776; 1847-1853; 1934-1939
  143. •Eliava, G. and Pozerski, E. (1921) ‘Sur les caracteres nouveaux presentes par le bacille de shiga ayant resiste a l’action du bacteriophage de d’Herelle‘ Compt Rend Soc Biol 84:708
  144. •Eliava, G. and Suarez, E. (1921) ‘Au sujet de l’ultrafiltration du corpuscule bacteriophage‘ Compt rend Soc Biol 84:460
  145. •Eliava, G. and Suarez, E. (1921) ‘Dimensions du corpuscule bacteriophage‘ Compt rend Soc Biol 84:462
  146. •Eliava, G. (1927) ‘Au sujet de l’adorption du bacteriophage par les leucocytes‘ Compt Rend Soc Biol 96:829
  147. •Ellis, E.L. and M. Delbrück (1939) ‘The Growth of Bacteriophage‘ J Gen Physiol 22:365-384
  148. •Emery D.L. and Whittington R.J. (2004) ‘An evaluation of mycophage therapy, chemotherapy and vaccination for control of Mycobacterium avium subsp. paratuberculosis infection‘ Vet Microbiol 104:143-55
  149. •Evans, A.C. (1935) ‘A comparative study of streptococcal immunity‘ Washington, U. S. Gov print off
  150. •Eyer, L. et al. (2007) ‘Structural protein analysis of the polyvalent staphylococcal bacteriophage 812.‘ Proteomics 7:64-72
  151. •Fairbrother, J.M. et al. (2005) ‘Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies‘ Anim Health Res Rev 6:17-39
  152. •Farrar, M.D. et al. (2007) ‘Genome Sequence and Analysis of a Propionibacterium acnes Bacteriophage‘ J Bact 189:4161-4167
  153. •Faruque, S.M. et al. (2005) ‘Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages‘ PNAS 102:1702-7
  154. •Faruque, S.M. et al. (2005) ‘Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages’ PNAS 102:1702–7
  155. •Fedorovich, D. P. (1944) ‘Bacteriophage therapy in gunshot wounds‘ Soviet med 8:26
  156. •Fischer, C.R. et al. (2004) ‘The coexistence of Escherichia coli serotype O157:H7 and its specific bacteriophage in continuous culture‘ FEMS Microbiol Lett 241:171-7
  157. •Fischetti, V.A. (2005) ‘Use of phage lytic enzymes for the treatment and control of bacterial pathogens‘ Shock 23:31-32
  158. •Fisk, R.T. (1938) ‘Protective action of typhoid phage on experimental
  159. •Flaherty, J.E. et al. (2000) ‘Control of bacterial spot on tomato in the greenhouse and field with h-mutant bacteriophage’ HortScience, 35:882–4
  160. •Fletcher, W. (1927) ‘The bacteriophage in the treatment of bacillary dysentery of the Flexner type‘ Bulletins from the Institute for medical research, Kuala Lumpur
  161. •Flu, P.C. (1923) Sur la pretendu action dechainante de la pancreatine sur le principe bacteriophage Compt Rend Soc Biol 87:970
  162. •Flu, P.C. and Renaux, E. (1932) ‘Le phénomène de Twort et la bactériophage‘ Ann Inst Pasteur 48:15-18
  163. •Flu, P.C. (1946) The Bacteriophage: A Historical and Critical Survey of 25 Years Research, Universitaire Pers Leiden, Leiden
  164. •Fokine, A. et al. (2007) ‘Cryo-EM Study of the Pseudomonas Bacteriophage piKZ‘ Structure 15:1099-104
  165. •Frenkel, D. and Solomon, B. (2002) ‘Filamentous phage as vector-mediated antibody delivery to the brain‘ PNAS 99:5675-5679
  166. •Frisbee, F.C. and MacNeal, W.J. (1942) ‘The use of bacteriophages in infected wounds and their sequelae‘ J Bact 43:67
  167. •Frisch, B. (1925) ‘Zur Behandlung der Koliinfektionen des Harntraktes mit Bakteriophagen‘ Wien Klin Wschr 38:839
  168. •Gabisonia T.G. et al. (1995) ‘Phagotherapy of nosocomial strains of P. aeruginosa belonging to different o-groups‘ Georg Med News 15:19-21
  169. •Gachechiladze, K.K. et al. (1991) ‘Host-controlled modification and restriction as a criterion of evaluating the therapeutical potential of Pseudomonas phage‘ J Basic Microbiol 31:101-106
  170. •Gaeng, S. et al. (2000) ‘Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis’ Appl Environ Microbiol 66:2951–8
  171. •Gaidelyte, A. et al. (2007) ‘Bacteria, Phages and Septecemia‘ PLoS ONE 2: e1145
  172. •Gantenberg, R. (1939) ‘Ruhr aus dem Feldzug in Polen 1939‘ Dtsch Med Wschr 65:1789
  173. •Geier, M.R. et al. (1973) ‘The fate of bacteriophage lambda in non-immune germ-free mice‘ Nature 246:221-223
  174. •genomics‘ Nat Biotechnol 22:185-91
  175. •Gildemeister, E. (1921) ‘Über das d’Herellesche Phänomen‘ Berlin Klin Wschr 58:1355
  176. •Girard, G. (1930) ‘Consideration sur le traitement de la peste par le bacteriophage‘ Bull Soc Path Exot Paris 23:936
  177. •Girard, G. (1931) ‘Consideration sur le traitement de la peste par le bacteriophage‘ Presse Med, 17. Jan. 1931
  178. •Glauser H.A. (1966) [‘Antiviral immunotherapy‘] Praxis 55:894-6
  179. •Glauser H.A. (1966) [‘Immunotherapy and chronic infections‘] Ther Umsch 23:293-5
  180. •Goodridge, L.D. (2004) ‘Bacteriophage biocontrol of plant pathogens: fact or fiction? ‘ Trends Biotechnol 22:384-5
  181. •Gorski, A. et al. (2005) ‘The potential role of endogenous bacteriophages in controlling invading pathogens‘ Cell Mol Life Sci 62:511-519
  182. •Gorski, A. et al. (2006) ‘Bacteriophage translocation‘ FEMS Immunol Med Microbiol 46:313-9
  183. •Gosset, M. (1929) ‘A propos des injections intraveineuses de bacteriophage‘ Presse Med 6. Nov 1929
  184. •Gratia A. (1921) ‘De l’adaptation hereditaire du colibacille a l’autolyse microbienne transmissible‘ Compt Rend Soc Biol 84:750
  185. •Gratia A. (1921) ‘De la signification des „colonies de bacteriophage“ de d‘Herelle‘ Compt Rend Soc Biol 84:753
  186. •Gratia A. (1921) ‘Dissociation d’une souche de colibacille en deux types d’individus de propriete et de virulence differentes‘ Compt Rend Soc Biol 84:751
  187. •Gratia A. (1921) ‘Influence de la reaction du milieu sur l’autolyse microbienne transmissible‘ Compt Rend Soc Biol 84:275
  188. •Gratia A. (1921) ‘Sur la specificite du principe lytique‘ Compt Rend Soc Biol 84:755
  189. •Gratia, A. (1921) ‘L‘autolyse transmissible du staph et l’action coagulante des cultures lysee‘ Compt Rend Soc Biol 84:25
  190. •Gratia, A. (1921) ‘Studies on the d’Herelle phenomenon‘ J Exp Med 34:115
  191. •Gratia, A. (1922) ‘La lyse transmisible du staphylocoque. Sa production, ses applications thérapeuthiques‘ Compt Rend Soc Biol 86:276
  192. •Gratia, A. and Kruif, L. (1923) ‘Tentative d’isolement de bacteriophages d’inegale activite, a partir d’un principe lytique coli manifestant des variation d‘energie‘ Compt Rend Soc Biol 87:629
  193. •Gratia, A. (1923) ‘Heterogenite du principe lytique du colibacille‘ Compt Rend Soc Biol 89:821
  194. •Gratia, A. (1931) ‘Sur l’identité du phénomene de Twort et du phénomene de d‘Herelle‘ Ann Inst Pasteur 46:1
  195. •Gratia, A. (1931) ‘Sur l’identité du phénomene de Twort la bacteriophagie (reponse a M d’Herelle) ‘ Ann Inst Pasteur 46:620
  196. •Gratia, A. (1931) ‘Recherches sur l’origine du bacteriophage du staphylocoque‘ Ann Inst Pasteur 46:622
  197. •Gratia, A. (1931) ‘Sur l’identité du phénomene de Twort la bacteriophagie (derniere reponse a M d’Herelle)‘ Ann Inst Pasteur 47:243
  198. •Greaves, J.E. (1926) ‘Do bacteria have diesease?‘ Scientific Monthly (1926/1)
  199. •Guthof, O. (1941) ‘Die Behandlung der Ruhr bei der Truppe mit Bakteriophagen‘ Deutsch Med Wschr 67:375
  200. •Haldenwanger, H. (1943) ‘Gesetzmässigkeiten in der Inaktivierung von Ruhrbakteriophagen durch Säuren und ihr Verhalten gegenüber Sulfonamiden‘ ZBL Bakt I Orig 151:323
  201. •Hankin, E.H. (1896) ‘L‘action bactericide des Eaux de la Jumna et du Gange sur le vibrion du cholera‘ Ann Inst Pasteur 10:511
  202. •Greer, G.G. and Dilts, B.D. (1990) ‘Inability of a bacteriophage pool to control beef spoilage‘ Int J Food Microbiol 10:331-342
  203. •Grimont, P.-A.D et al. (1978) ‘Traitement d'une endocardite à Serratia par les bactériophages‘  Nouv Presse Med 7:2251
  204. •Hagens, S. and Bläsi, U. (2003) ‘Genetically modified filamentous phage as bactericidal agents: a pilot study‘ Lett Appl Microbiol 37:318
  205. •Hagens, S. et al. (2004) ‘Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage‘ Antimicrob Agents Chemother 48:3817-22
  206. •Hanlon, G.W. et al. (2001) ‘Reduction in Exopolysaccharide Viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms‘ Appl Env Microbiol 67:2746-53
  207. •Hasting, A.B. and Shimkin, M.B. (1946) ‘Medical Research Mission to the Soviet Union‘ Science 103:605-608
  208. •Hauduroy, P. (1922) Compt Rend Soc Biol 85:964
  209. •Hauduroy, P. (1922) Compt Rend Soc Biol 85:966
  210. •Hauduroy, P. (1931) ‘La therapeutique par le bacteriophage: ses avantages, ses dangers‘ Presse Med 10:168-171
  211. •Hauduroy, P. (1946) ‘La therapeutique par le bacteriophage‘ Presse Med 51:703-704
  212. •Hauduroy, P. and Rosset (1963) ‘Tentative traitement des hamsters inocules avec le BCG (Mycobacterium) par un bacteriophage‘ Ann Inst Pasteur 104:419-20
  213. •Häusler, T. (2003) Gesund durch Viren, Piper
  214. •Häusler, T. (2006) Viruses vs. Superbugs, Macmillan
  215. •Hedström, S.A. and Kamme, C. (1973) ‘Antibodies against staphylococcal bacteriophages in human sera. II. Assay of antibodies in exacerbation and regression of chronic staphylococcal osteomyelitis‘ Acta Pathol Microbiol Scand (B) 81:749-752
  216. •Hendrix, R.W. (2002) ‘Bacteriophages: Evolution of the majority‘ Theoret Popul Biol 61:471-480
  217. •Hermoso, J.L. et al. (2007) ‘Taking aim on bacterial pathogens: from phage therapy to enzybiotics.‘ Curr Opin Microbiol 10:461-72
  218. •Hildebrand, G.J. and Wolochow, H. (1962) ‘Translocation of bacteriophage across the intestinal wall of the rat‘ Proc Soc Exp Biol Med 109:183-185
  219. •Hoder, F. (1936) ‘Die Verwendbarkeit der Bakteriophagen in der Therapie‘ Zschr ärztl Fortbldg 33:393
  220. •Kabeshima, T. (1920) ‘Sur un ferment d’immunite bacteriolysant, du mechanisme d’immunite infectieuse intestinale, de la nature du dit „microbe filtrant bacteriophage“ de d‘Herelle‘ Compt Rend Soc Biol 83:219
  221. •Hoffmann, M. (1965) ‘Animal experiments on mucosa passage and absorbtion viremia of T3 phages after oral, tracheal, and rectal administration‘ (German) Zentralbl Bakteriol 198:371-390
  222. •Holzman, D. (1998) ‘Phage as antibacterial tool‘ Gen Engin News 18:1-48
  223. •Holzman, D. (1998) ‘Reassessment of medicinal phage‘ ASM News 64:620-622
  1. •Huff W.E. et al. (2003) ‘Bacteriophage treatment of a severe Escherichia coli respiratory infection in broiler chickens‘ Avian Dis 47:1399-405
  2. •Huff, W.E. et al. (2004) ‘Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers‘ Poult Sci 83:1944-7
  3. •Huff, W.E. et al. (2005) ‘Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens‘ Poult Sci 84:655-9
  4. •Hughes, K.A. (1998) ‘Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase‘ Microbiology 144:3039–3047
  5. •Inal, J.M. (2003) ‘Phage therapy: a reappraisal of bacteriophages as antibiotics‘ Arch Immunol Ther Exp (Warsz) 51:237-44
  6. •Iriarte, F. B. (2007) ‘Factors Affecting Survival of Bacteriophage on Tomato Leaf Surfaces‘  Appl Environ Microbiol 73:1704-1711
  7. •Jadin, J. and Resseler, J. (1957) ‘La dysenterie bacillaire au Ruanda-Urundi et au Kivu’ Ann Soc Belge Med Trop 37:347–69
  8. •Jikia, D. et al. (2005) ‘The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90‘ Clin Exp Dermatol 30:23-6
  9. •Joerger, R.D. (2003) ‘Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages‘ Poult Sci 82:640-7
  10. •Kabeshima, T. (1920) ‘Sur le ferment d’immunite bacteriolysant‘ Compt Rend Soc Biol 83:471
  11. •Kalinke, M. (1941) ‘Die Ruhrbehandlung mit Polyfagin und Darmdesinfizienten‘ Med Welt 15 II:785
  12. •Kamme, C. (1973) ‘Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections‘ Acta Pathol Microbiol Scand (B) 81:741-748
  13. •Karpisek, J. (1947) ‘Contribution a l’emploi du bacteriophage dans le traitement de la dysenterie bacillaire‘ Presse Med 52:422
  14. •Kasman, L. M. et al. (2002) ‘Overcoming the phage replication threshold: a mathematical model with implications for phage therapy‘ J Virol 76:5557-64
  15. •Kellenberger, E. (1995) ‘History of phage research as viewed by a European‘ FEMS Microbiol Rev 17:7-24
  16. •Keller, R. and Engley, F.B. (1958). ‘Fate of bacteriophage particles induced into mice by various routes‘ Proc Soc Exp Biol Med 98:577
  17. •Keller, R. and Zatzman, M.L. (1959) ‘Studies on the factors concerned in the disappearance of bacteriophage particles from the animal body‘ J Immunol 83:167
  18. •Kliewe, H. and Helmreich, W. (1941) ‘Über Ruhrbakteriophagen‘ Münch Med Wschr 88:617
  19. •Klose, F. and Schröder W. (1941) ‘Ein Beitrag zur Ruhrschutzbehandlung mit polyvalenten Ruhrbakteriophagen‘ Dtsch Mil Arzt 6:265
  20. •Kludas, M. and Flach, C.H. (1951) ‘Bakteriophagentherapie bei akuten und chronischen Darmerkrankungen‘ Med Klin 46:769
  21. •Kludas, M. and Krug, K. (1951) ‘Bakteriophagen bei Darmerkrankungen‘ Ärztl. Wschr 42:1000
  22. •Knouf E.G. et al. (1946) ‘Treatment of typhoid fever with type specific bacteriophage‘ JAMA 132:134
  23. •Koch, S. et al. (2004) ‘Treatment and prevention of enterococcal infections - alternative and experimental approaches‘ Expert Opin Biol Ther 4:1519-31
  24. •Kochetkova, V.A. et al. (1989) [‘Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms‘]. [Russian]. Sovet Med 23-26
  25. •Kozminska, J. et al. (1997) ‘The study on biology of bacteriophages and their usage in the treatment of bacterial diseases and on the influence of different bacteriophages on cytokine production by leukocytes in human peripheral blood‘ (Polish) Otolaryngol Polska 51 Suppl 25:195-198
  26. •Krestovnikova, V.A. (1947) ‘Phage therapy and phage prophylaxis and their justification in the studies of Soviet researchers‘ Zhurn mikrobiol epidemiol immunobiol N3:56–65
  27. •Krueger, A.P. and Northrop, J.H. (1931) ‘The Kinetics of the Bacterium-Bacteriophage Reaction‘ J Gen Physiol 14:223
  28. •Krueger, A.P. and Scribner, E.J. (1941) ‘The bacteriophage: Its nature and its therapeutic use (I)‘ JAMA 116:2160-2167
  29. •Krueger, A.P. and Scribner, E.J. (1941) ‘The bacteriophage: Its nature and its therapeutic use (II)‘ JAMA 116:2269-2277
  30. •Kucharewicz-Krukowska, A. and Slopek, S. (1987) ‘Immunogenic effect of bacteriophage in patients subjected to phage therapy‘ Archiv Immunolog Therap Exp 35:553-561
  31. •Kudva, I.T. et al. (1999) ‘Biocontrol of Escherichia coli O157 with O157-specific bacteriophages‘ Appl Environ Microbiol 65:3767-3773
  32. •Kutter, E. and Sulakvelidze, A. (2005) Bacteriophages – Biology and applications, CRC Press
  33. •Kutter, E. et al. (1994) ‘Effects of Bacterial Growth Conditions and Physiology on T4 Infection‘ pp. 406-420. in J. D. Karam (ed.), Molecular Biology of Bacteriophage T4 American Society for Microbiology
  34. •Kutter, E. et al. (1996) ‘Evolution of T4-related phages‘ Virus Genes 11:285-297
  35. •Kwarcinski, W. et al. (1994) ‘Bacteriophage therapy in the treatment of recurrent subphrenic and subhepatic abscess with jejunal fistula after stomach resection‘ (Polish). Polski Tygod Lekarski 49:535-535
  36. •Kysela, D. T. et al. (2007) ‘Optimal bacteriophage mutation rates for phage therapy‘ J Theor Biol 249:411-21
  37. •Lang, G. et al. (1979) ‘Bacteriophage treatment of septic complications of orthopaedic surgery‘ Rev Chir Orthrop Reparat Appar Mot 1:33-37
  38. •Lavigne, R. et al. (2003) ‘The genome of bacteriophage phiKMV, a T7-like virus infecting Pseudomonas aeruginosa‘ Virology 312:49-59
  39. •Lederberg, J. (1996) ‘Smaller Fleas ... ad infinitum: Therapeutic Bacteriophage‘ PNAS 93:3167-3168
  40. •Lenz, O. (1944) ‘Enterofagos als Prophylaktikum gegen Scharlach‘ Münch Med Wschrift 91:73
  41. •Leruitte, A. et al. (1979) [‘Microbiological approach to urinary infections with Pseudomonas aeruginosa‘] Acta Urol Belg 47:683-701
  42. •Leverentz, B. et al. (2003) ‘Biocontrol of Listeria monocytogenes on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin’ Appl Environ Microbiol 69:4519–26
  43. •Levin, B. and Bull, J.J. (1996) ‘Phage Therapy Revisited: The Population Biology of a Bacterial Infection and its Treatment with Bacteriophage and Antib iotics American Nat 147:881-898
  44. •Levin, B.R. and Bull J. J. (2004) ‘Population and evolutionary dynamics of phage therapy‘ Nat Rev Microbiol 2:166-73
  45. •Ligny, G. (1963) ‘Les diarrhees aigues et chroniques de l’adulte interet therapeutique du bacteriophage‘ Sem Hop (Sem therapeutique) 8:499-505
  46. •Lippelt, H. (1939) ‘Zur Frage der Bakteriophagenbehandlung‘ Dtsch med Wschr 64:1102
  47. •Liu, J. et al. (2004) ‘Antimicrobial drug discovery through bacteriophage‘ Nat Biotechnol 22:185-91
  48. •Liu, M. et al. (2002) ‘Reverse transcriptase-medicated tropism switching in Bordetella bacteriophage‘ Science 295:2091–4
  49. •Loc Carillo, C. et al. (2005) ‘Bacteriophage Therapy To Reduce Campylobacter jejuni Colonization of Broiler Chickens‘ Appl Environ Microbiol 71:6554-63
  50. •Loeffler, J.M. et al. (2001) ‘Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase’ Science 294:2170–2
  51. •Loeffler J.M. et al. (2003) ‘Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia‘ Ifect Immun 71:6199-6204
  52. •Lowbury, E.J.L. and Hood, A.M. (1953) ‘The acquired resistance of Staphylococcus aureus to bacteriophage‘ J Gen Microbiol 9:524-535
  53. •Lu, T. K. et al. (2007) ‘Dispersing biofilms with engineered Dispersing biofilms with engineered enzymatic bacteriophage‘ PNAS 104:11197–11202
  54. •MacNeal, W.J. (1931) ‘Therapeutic and prophylactic use of bacteriophages‘ J Bact 45:76
  55. •MacNeal, W.J. (1934) ‘Using the enemy of bacteria to combat disease’ Lit Dig 117:17
  56. •MacNeal, W.J. et al. (1941) ‘Bacteriophage service in staphylococcal infections‘ Am J Clin Pathol 11:549
  57. •MacNeal, W.J. et al. (1946) ‘Conjoined action of penicillin and bacteriophages‘ J Lab Clin Med 31:974
  58. •Maisin, J. (1921) ‘Au sujet du principe bacteriophage et des anticorps‘ Compt Rend Soc Biol 84:755
  59. •Mankiewicz, E. and Liivak, M. (1967) ‘Mycobacteriophages isolated from human sources‘ Nature 216:485-6
  60. •Marcuk, L.M. et al. (1971) ‘Clinical studies of the use of bacteriophage in the treatment of cholera‘ Bull World Health Org 45:77-83
  61. •Marcuse, K. (1926) ‘Untersuchungen über das d’Herelle’sche Phänomen. III. Beziehungen zwischen Bakteriophagie und Agglutination (Rezeptorenstudien) ‘ Zschr. Hyg 105:17
  62. •Markoishvili, N. et al. (1999) ‘PhageBioDerm - new prospects for treatment of wounds and trophic ulcers‘ Exp Clin Med 2:83-84
  63. •Markoishvili, K. et al. (2002) ‘A novel sustained-released matrix based on biodegradable polyester amides and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds’ Int J Dermatol 41:453–8
  64. •Mathur, M.D. et al. (2003) ‘Bacteriophage therapy: an alternative to conventional antibiotics‘ J Assoc Physicians India 51:593-6
  65. •Matsuda, T. et al. (2005) ‘Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model‘ Surgery 137:639-46
  66. •Matsuzaki, S. et al. (2003) ‘Experimental Protection of Mice against Lethal Staphylococcus aureus Infection by Novel Bacteriophage phiMR11‘ J Infect Dis 187:613-24
  67. •Matsuzaki, S. et al. (2005) ‘Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases‘ J Infect Chemother 11:211-9
  68. •Matusis Z.E. et al. (1967) ‘Effektivnost' fagoterapii pri eksperimental'noi proteinoi infektsii‘ [‘Effectiveness of phage therapy in experimental proteus infection‘] Zhun Mikrobiol Epidemiol Immunobiol 44:100-3
  69. •Mazacek, M. and Kumbera, V. (1959) ‘L’emploi de bacteriophages dysenteriques monvalents desseches a la therapie et prophylaxie de la dysenterie bacillaire‘ Compt Rend Symp Intern Immunol Opatija 39-42
  70. •Mazácek, M. et al. (1969) ‘Die Bakteriophagie in der Therapie und Prophylaxe der Infektionskranheiten‘ Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt 1 Orig Reihe A 211:385-394
  71. •McGrath et al. (2004) ‘The impact of bacteriophage genomics‘ Curr Opin Biotechnol 15:94-9
  72. •McKenna, F. et al. (2001) ‘Novel in vivo use of a polyvalent Streptomyces phage to disinfest Streptomyces scabies-infected seed potatoes‘ Plant Pathol 50:666-675
  73. •McVay, C. S. et al. (2007) ‘Phage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model‘  Antimicrob Agents Chemother 51:1934-1938
  74. •Merril, C.R. et al. (1971) ‘Bacterial virus gene expression in human cells’ Nature 233:398–400
  75. •Merril, C. et al. (1972) ‘Isolation of bacteriophages from commercial sera‘ In Vitro 8:91-93
  76. •Merril, C. et al. (1996) ‘Long-circulating bacteriophages as antibacterial agents‘ PNAS 93:3188-3192
  77. •Merril, C. R. et al. (2003) ‘The prospect for bacteriophage therapy in Western medicine‘ Nat Rev Drug Discov 2:489-97
  78. •Mesyanzhinov, V.V. et al. (2002) ‘The Genome of Bacteriophage phiKZ of Pseudomonas aeruginosa‘ J Mol Biol 317:1-19
  79. •Miller, R.V. and Renta Rubero, J.R. (1984) ‘Mucoid conversion by phages of Pseudomonas aeruginosa strains from patients with cystic fibrosis‘ J Clin Microbiol 19:717
  80. •Monsur, K.A. et al. (1970) ‘Effect of massive dosis of bacteriophage on excretion of vibrio, duration of diarrhoea and output of stools in acute cases of cholera‘ Bull WHO 42:723-32
  81. •Morison, J. (1932) Bacteriophage in the Treatment and Prevention of Cholera, H.K. Lewis
  82. •Morison, J. et al. (1934) ‘Bacteriophage in the treatment and prevention of Cholera‘ Ind J Med Res 21:789
  83. •Morison, J. et al. (1934) ‘Bacteriophage, essential oils and vaccination and their effects on cholera mortality‘ Ind J Med Res 22:317
  84. •Morison, J. (1935) ‘Bacteriophage in cholera‘ Trans Roy Soc Trop Med Hyg 28:563-570
  85. •Morton, D. and Bardhan, K.D. (2000) ‘Bacteriophages active against Helicobacter pylori in UK sewage: Natural born killers?‘ Gastroenterology 118:89
  86. •Morton, D. and Bardhan, K.D. (2000) ‘The presence of bacteriophages active against Helicobacter pylori in UK sewage: Natures eradicator? ‘ Gut 46:A69
  87. •Morton, H.E. and Engley F.B. (1945) ‘The protective action of dysentery bacteriophage in experimental infections in mice‘ J Bact 49:245
  88. •Morton, H.E. and Engley, F.B. (1945) ‘Dysentery bacteriophage’ JAMA 127: 584–91
  89. •Morton, H.E. and Perez-Otero J. (1945) ‘The increase of bacteriophage in vivo during experimental infections with Shigella paradysenteriae in mice‘ J Bact 49:237
  90. •Mudd, S. (1947) ‘Recent observations on programs for medicine and national health in the USSR, part 2‘ Amer Rev Soviet Med 5:71-81
  91. •Munter, H. and Boenheim, C. (1925) ‘Über therapeutische Versuche mit bakteriophagem Lysin bei Kindern und Saüglingen‘ Zeitschr Kinderheilk 39:388
  92. •Myedzibrodzki, R. et al. (2007)‘Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment.‘ Postepy Hig Med Dosw (Online) 61:461-465
  93. •Naidu, B.P.B. and Avari, C.R. (1932) ‘Bacteriophage in the treatment of plague‘ (1932) Ind J Med Res 19:737
  94. •Nakai, T. and Park, S.C. (2002) ‘Bacteriophage therapy of infectious diseases in aquaculture‘ Res Microbiol 153:13-18
  95. •Nattan-Larrier et al. (1927) ‘Bacteriophage et permeabilite placentaire‘ Compt Rend Soc Biol 96:794
  96. •Nelson, D. et al. (2001) ‘Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme’ PNAS 98:4107–12
  97. •Nikusch, R. (1941) ‘Über vergleichende Behandlung der Bazillenruhr‘ Dtsch Mil-Arzt 6:361
  98. •Norris, J.S. et al. (2000) ‘Procaryotic gene therapy to combat multidrug resistant bacterial infection’ Gen Ther 7:723–5
  99. •Ochs, H.D. et al. (1992) ‘Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency‘ Blood 5:1163-1171
  100. •Otto, R. and Munter H. ‘Zum d'Herelleschen Phänomen‘ Dtsch Med Wschr 47:1579
  101. •Paisano, A.F. et al. (2004) ‘In vitro antimicrobial effect of bacteriophages on human dentin infected with Enterococcus faecalis ATCC 29212‘ Oral Microbiol Immunol 19:327-30
  102. •Pandit, S.R. (1951) ‘A note on cholera in Assam and the cholera bacteriophage experiment carried out in Assam‘ Ind J Med Res 39:197
  103. •Paradis-Bleau, C. et al. (2007) ‘Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage phiKZ gp144 lytic transglycosylase.‘ FEMS Microbiol Lett 266:201-9
  104. •Park, S.C. and Nakai, T. (2003) ‘Bacteriophage control of Pseudomonas plecoglossicida infection in ayu Plecoglossus altivelis‘ Dis Aquat Organ 53:33-9
  105. •Pasricha, C.L. et al. (1936) ‘Bacteriophage in the treatment of cholera‘ Ind Med Gaz 71:61-68
  106. •Payne, R.J.H. et al. (2000) ‘Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals‘ Clin Pharmacol Ther 68:225-230
  107. •Payne, R.J.H. and Jansen, V.A.A. (2001) ‘Understanding bacteriophage therapy as a density-dependent kinetic process‘ J Theor Biol 208:37-48
  108. •Payne R.J.H. and Jansen, V. A. A. (2003) ‘Pharmacokinetic principles of bacteriophage therapy‘ Clin Pharmacokinet 42:315-25
  109. •Peitzman, S.J. (1969) ‘Felix d'Herelle and bacteriophage therapy‘ Trans Stud Coll Phys Phil 37:115-123
  110. •Perepanova T.S. et al. (1995) ‘Effektivnost' preparatov bakteriofagov pri lechenii vospalitel'nykh urologicheskikh zabolevanii‘ [‘The efficacy of bacteriophage preparations in treating inflammatory urologic diseases‘] Urol Nefrol (Mosk) 5:14-7
  111. •Pesch, K.L. and Raentsch, F. (1940) ‘Die Bakteriophagentherapie‘ Weich Erg Hyg 23:264
  112. •Pfankuch, E. and Kausche, G.A. (1940) ‘Isolierung und Übermikroskopische Abbildung eines Bakteriophagen‘ Naturwiss 28:46
  113. •Pillich, J. et al. (1969) [‘Assumptions for successful therapy using staphylococcal phage lysates‘] [German] Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt 1 Med Hyg Bakteriol Virusfor Parasitol - Originale 210:377-381
  114. •Platt, R. et al. (2003) ‘Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system‘ FEMS Microbiol Lett 223:259-65
  115. •Pockels, W. (1927) ‘Die Bakteriophagentherapie in der Kinderheilkunde’ Mschr Kinderheilkun 35:229-236
  116. •Pollitzer, R. (1959) Cholera World Health Organization
  117. •products’ JAMA 100:110–13
  118. •Prangishvili, D. (2007) ‘Editorial: the 90th anniversary of“bacteriophage“‘Res Microbiol 158:551-552
  119. •Projan, S. (2004) ‘Phage inspired antibiotics?‘ Nat Biotechnol 22:167-8
  120. •Raettig, H. (1958/1967) Bakteriophagie and Bakteriophagie 1957–1965, Gustav Fischer
  121. •Raiga, A. (1930) ‘Traitement des mastites aigues de l’allaitement par le bactériophage de d’Herelle‘ Presse Med 8. Feb, p. 197
  122. •Raiga-Clemenceau A. (1974) ‘D’Herelle’s bacteriophage and it’s therapeutic property‘ Sem Hop Ther March 50:229-31
  123. •Rakieten, M.L. (1932) ‘Studies with staphylococcal bacteriophage I. The preparation of polyvalent staphylococcal bacteriophage‘ Yale J Biol Med 4:807
  124. •Rakieten, M.L. and Rakieten, T.L. (1938) ‘The inactivation of "pure line" phages by bacterial extracts and the loss of phage types in vivo‘ Yale J Biol Med 10:191-208
  125. •Ranjan, A. et al. (2007) ‘Evaluation of codon bias perspectives in phage therapy of Mycobacterium tuberculosis by multivariate analysis.‘ In Silico Biol 7:30
  126. •Rdamesh, V. et al. (1999) ‘Bacteriophage therapy of Clostridium difficile-associated intestinal disease in a hamster model‘ Miroecol Anarobes 5:69
  127. •Reynaud, A. et al. (1992) ‘Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy‘ Vet Microbiol 30:203-212
  128. •Rice, T.B. (1930) ‘Use of bacteriophage filtrates in treatment of suppurative conditions: report of 300 cases‘ Am J Med Sci 179:345-360
  129. •Robertson, R.C. (1929) ‘Experimental work with bacteriophage‘ China Med J 43,795
  130. •Rivers, T.M. (1927) ‘Filtrable Viruses‘ J. Bac 14: 217-257
  131. •Ruska, H. (1940) ‘Über die Sichtbarmachung der bakteriophagen Lyse im Übermikroskop‘ Naturwiss 28:45-46
  132. •Ruska, H. (1943) ‘Ergebnisse der Bakteriophagenforschung und ihre Deutung nach morphologischen Befunden‘ Ergeb Hyg Bakteriol Immunforsch Exp Ther 25:437-498
  133. •Rybniker, J. et al. (2006) ‘Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis - application for identification and susceptibility testing‘ J Med Microbiol 2006 55:37-42
  134. •Samsygina G.A. and Boni, E.G. (1984) ‘Bacteriophages and phage therapy in pediatric practice‘ (Russ) Pediatriia 4:67-70
  135. •Sasha, S.M. et al. (2004) [‘Bacteriophages as antibacterial agents‘] Harefuah 143:121-5
  136. •Sau, K. et al. (2005) ‘Synonymous codon usage bias in 16 Staphylococcus aureus phages: Implication in phage therapy‘ Virus Res 113:123-31
  137. •Sayamov, R.M. (1963) ‘Treatment and prophylaxis of cholera with bacteriophage‘ Bull WHO 28:361-367
  138. •Schade, A.L. and Caroline, L. (1943) ‘The preparation of a polyvalent dysentery bacteriophage in a dry and stable form’ J Bact 46:463–73
  139. •Schade, A.L. and Caroline, L. (1944) ‘The preparation of a polyvalent dysentery bacteriophage in a dry and stable form’ J Bact 48:179–90, 243–51
  140. •Schlesinger, M. (1933) ‘Reindarstellung eines Bakteriophagen in mit freiem Auge sichtbaren Mengen‘ Biochem Zschr 264:6
  141. •Schless, R.A. (1932) ‘Staphylococcus aureus meningitis: treatment with specific bacteriophage‘ Am J Dis Child 44:813-822
  142. •Schmidt, H. (2001) ‘Shiga-toxin-converting bacteriophages Res Microbiol 152:687-695
  143. •School, D. et al. (2001) ‘Bacteriophage K1-5 encodes two different tail fibre proteins, allowing it to infect and replicate on both K1 and K strains of Escherichia coli ’ J Virol 75:2509–15
  144. •Schubbert, R. et al. (1994) ‘Ingested foreign (phage M13)DNA survives transiently in the gastrointestinal tract and enters the blood stream of mice‘ Mol Gen Genet 242:495-504
  145. •Schuch, R. et al. (2002) ‘A bacteriolytic agent that detects and kills Bacillus anthracis’ Nature 418:884–9
  146. •Schultz, E.W. (1930) The ultramicroscopic viruses from the biological standpoint‘ Scientific Monthly (Science, 1930/1
  147. •Sedallian, P. et al. (1958) ‘Méningite purulente à colibacilles traitée par un bactériophage adaptée intrarachidien‘ Lyon Med :509-512
  148. •Seidlmayer, H. (1939) ‘Die Behandlung der Ruhr im Kindesalter mit Bakteriophagen‘ Zeitschr Kinderh 60:579-589
  149. •Seiffert, G. (1941) ‘Über die Verwendung von Bakteriophagen zur Ruhrbekämpfung‘ Münch Med Wschr 88:641
  150. •Shera, G. (1970) ‘Phage treatment for severe burns‘ BMJ 1:568-569
  151. •Shishniashvili, T.E. (1999) ‘The use of "Phagedent" for treatment of parodontium diseases‘ Exp Clin Medicine 2:128-129
  152. •Shrayer, D. (1989) ‘Staphylococcal disease in the Soviet union. Epidemiology and response to a national epidemic‘ Delphic Associates
  153. •Shrayer, D. (1996) ‘Felix d'Herelle in Russia‘ Bull Inst Pasteur 94:91-96
  154. •Skurnik, M. et al. (2007) ‘Biotechnological challenges of phage therapy.‘ Biotechnol Lett 29:995-1003
  155. •Stent, G. (1965) ‘Papers on Bacterial Viruses‘ Little, Brown and Co.
  156. •Summers, W.C. (2001) ‘Bacteriophage Therapy‘ Ann Rev Microbiol 55:437-451
  157. •Summers, W.C. (1991) ‘On the Origins of the Science in Arrowsmith: Paul de Kruif, Felix d'Herelle and Phage‘ J Hist Med Allied Sci 46:315-332
  158. •Summers, W.C. (1993) ‘Cholera and Plague in India: The Bacteriophage Inquiry of 1927-1936‘ J Hist Med Allied Sci 48:275-301
  159. •Summers, W.C. (1999) Félix d'Herelle and the Origins of Molecular Biology Yale University Press
  160. •Skurnik, M. and Strauch, E. ‘Phage therapy: Facts and fiction‘ Int J Med Microbiol 296:5-14
  161. •Slopek, S. et al. (1981) ‘Results of Bacteriophage Treatment of Suppurative Bacterial Infections II. Detailed Evaluation of the Results‘ Arch Immunol Ther Exp 31:293-327
  162. •Slopek, S. et al. (1983) ‘Results of Bacteriophage Treatment of Suppurative Bacterial Infections I. General Evaluation of the Results‘ Arch Immunol Ther Exp 31:267-291
  163. •Slopek, S. et al. (1984) ‘Results of Bacteriophage Treatment of Suppurative Bacterial Infections III. Detailed Evaluation of the Results Obtained in Further 150 Cases‘ Arch Immunol Ther Exp 32:317-335
  164. •Slopek, S. et al. (1985) ‘Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases‘ Arch Immunol Ther Exp 33:219-40
  165. •Slopek, S. et al. (1985) ‘Results of Bacteriophage Treatment of Suppurative Bacterial Infections VI. Analysis of treatment of supperative staphylococcal infections‘ Arch Immunol Ther Exp 33:261-273
  166. •Slopek, S. (1985) ‘Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children‘ Arch Immunol Ther Exp 33:241-59
  167. •Slopek, S. (1987) ‘Results of Bacteriophage Treatment of Suppurative Bacterial Infections in the Years 1981-1986‘ Arch Immunol Ther Exp 35:569-583
  168. •Smith, H.W. and Huggins, R.B. (1982) ‘Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics‘ J Gen Microbiol 128:307-318
  169. •Smith, H.W. and Huggins, R.B. (1983) ‘Effectiveness of phages in treating experimental E. coli diarrhoea in calves, piglets and lambs‘ J Gen Microbiol 129:2659-2675
  170. •Smith, H.W. and Huggins, R.B. (1987) ‘The Control of Experimental E. coli Diarrhea in calves by means of Bacteriophage‘ J Gen Microbiol 133:1111-1126
  171. •Smith, H.W. et al. (1987) ‘Factors influencing the Survival and Multiplication of Bacteriophages in Calves and in their Environment‘ J Gen Microbiol 133:1127-1135
  172. •Solodovnikov, Y.P. et al. (1970) ‘Prophylactic Application of Dry Polyvalent Dysentery Bacteriophage with Pectin in Children’s Preschool‘ (Russ.) Zhurn Mikrobiol Epidemiol Immunobiol 47:131-137
  173. •Solodovnikov, Y.P. et al. (1971) ‘Foundations of tactics and scheme of application of bacteriophage‘Zhurn Mikrobiol Epidemiol Immunobiol 48:123-127
  174. •Sonnenschein, C. (1933) ‘Therapeutische Anwendung von Bakteriophagen, insbesondere beim Typhus‘ Klin Wschr 54:685
  175. •Sonnenschein, C. (1935) ‘Eigene Erfahrungen mit der Bakteriophagentherapie bakterieller Infektionskrankheiten, insbesondere des Typhus‘ Zbl Bakt I Orig 135:171
  176. •Sonnenschein, C. (1938) ‘Weitere Erfahrungen mit der Bakteriophagenbehandlung‘ Zbl inn Med 59:537
  177. •Soothill, J.S. et al. (1988) ‘The efficacy of phages in the prevention of the destruction of pig skin in vitro by Pseudomonas aeruginosa‘ Med Sci Res 16:1287-1288
  178. •Soothill, J.S. (1992) ‘Treatment of experimental infections of mice with bacteriophages‘ J Med Microbiol 37:258-262
  179. •Soothill, J.S. (1994) ‘Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa‘ Burns 20:209-211
  180. •Spence, R.C. and McKinley, E.B. (1924) ‘The therapeutic value of bacteriophage in the treatment of bacillary dysentery‘ South edM J 17:563
  181. •Steinmann, J. (1937) ‘Injections de bacteriophage intracarotidien pour le traitement des furoncles du nez avec debut d’extension vers le sinus caverneux‘ Schweiz Med Wschr 18:1139
  182. •Steinmann, J. (1937) ‘Phlegmon du nez‘ Schweiz Med Wschr 18:1220
  183. •Steinmann, J. (1946) ‘Le Bactériophage: Sa nature et son emploi thérapeutique‘ habilitation, University of Geneva
  184. •Straub, M.E. and Applebaum, M. (1932) ‘Studies of commercial bacteriophage
  185. •Strauch, E. et al. (2001) ‘Characterization of Enterocoliticin, a Phage Tail-Like Bacteriocin, and Its Effect on Pathogenic Yersinia enterocolitica Strains‘ Appl Envir Microbiol 67:5634-42
  186. •Stroj, L. et al. (1999) [‘Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn‘]. Neurol Neurochir Polska 33:693-698
  187. •Sulakvelidze, A. and Morris, J.G. (2001) ‘Bacteriophages as therapeutic agents‘ Ann Med 33:507-509
  188. •Sulakvelidze A. et al. (2001) ‘Bacteriophage therapy‘ Antimicrob Agent Chemother 45:649-59
  189. •Sulakvelidze, A. (2005) ‘Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections‘ Drug Discov Today 10:807-9
  190. •Switala-Jelen, K. et al. (2002) ‘Mutations in bacteriophage T4 genome‘ Acta virol 46:57-62
  191. •Thacker, P.D. (2003) ‘Set a microbe to kill a microbe: drug resistance renews interest in phage therapy‘ JAMA 290:3183-5
  192. •Thiel, K. (2004) ‘Old dogma, new tricks - 21st Century phage therapy‘ Nat Biotechnol 22:31-6
  193. •Tietz, C.J. et al. (1943) ‘Untersuchungen über die Eubasintherapie auf die Darmbakterienflora und die Phagenentwicklung‘ Zbl Bakt I Orig 150:319
  194. •Toro, H. (2005) ‘Use of bacteriophages in combination with competitive exclusion to reduce Salmonella from infected chickens‘ Avian Dis 49:118-24
  195. •Twort, F.W. (1915) ‘An investigation on the nature of ultramicroscopic viruses‘ Lancet 1915 II:1241
  196. •Twort, F.W. (1920) ‘Researches on dysentery‘ Brit J Exp Path 1:237-43
  197. •Twort, F.W. (1931) ‘Les agents bacteriolytiques filtrables et transmissbles (bacteriophage)‘ Ann Inst Pasteur 47:32
  198. •Twort, F.W. (1949) ‘The discovery of the bacteriophage‘ Science News (Penguin), 14:33-43
  199. •typhoid infection in mice’ Proc Soc Exp Biol Med 38:659–60
  200. •Uhr, J.W. and Weissmann, G. (1965) ‘Intracellular distribution and degradation of bacteriophage in mammalian tissues‘ J Immunol 94:544
  201. •Van Helvoort, T. (1992) ‘Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon‘ Med Hist 36:243-270
  202. •Verbeken, J. et al. (2007) ‘European regulatory conundrum of phage therapy.‘ Future Microbiol 2007 2:485-91
  203. •Vieu, J.-F. et al. (1974) ‘Bacteriophages contaminant les preparations de serum de veau pour cultures de tissues‘ C R Acad Sci Paris 279:615-618
  204. •Vieu, J.-F. (1975) ‘Les Bacteriophages‘ in Traite de Therapeutique, Vol. Serums et Vaccins Flammarion, Paris, p.337-40
  205. •Vieu, J.-F. et al (1979) ‘Donnees actueles sur les applications therapeutiques des bacteriophages‘ Bull Acad Natl Med 163:61
  206. •Vitiello, C.L. et al. (2005) ‘An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than 1000-fold‘ Virus Res 114:101-103
  207. •Wagenaar, J.A. et al. (2001) ‘Phage therapy of Campylobacter jejuni colonization in broilers‘ Int J Med Microbiol 291:92-93
  208. •Wagenaar, J.A. et al. (2005) ‘Phage therapy reduces Campylobacter jejuni colonization in broilers‘ Vet Microbiol 109:275-83
  209. •Wahl, R. (1942) ‘Therapeutische Möglichkeiten und Wege im Sinne der Bakteriophagen- und Antivirusapplikationen‘ Wien Klin Wschr 55:952
  210. •Waksman, S.A. (1947) ‘Microbiology in the USSR in 1946‘ Scientific monthly 64:289
  211. •Waldor, M.K. and Mekalanos, J.J. (1996) ‘Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin‘ Science 272:1910-4
  212. •Wang, J. et al. (2006) ‘Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa‘ Int J Mol Med 17:309-17
  213. •Ward, W. E. (1943) ‘Protective action of Vi bacteriophage in Eberthella typhi infections in mice’ J Inf Dis 72:172–6
  214. •Watanabe, R. et al. (2007) ‘Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice.‘ Antimicrob Agents Chemother 51:446-52
  215. •Weber-Dabrowska, B. et al. (1987) ‘Studies on Bacteriophage Penetration in Patients Subjected to Phage Therapy‘ Arch Immunol Ther Exp 35:563-568
  216. •Weber-Dabrowska, B. et al. (2000) ‘Bacteriophage therapy of bacterial infections: an update of our institute’s experience‘ Arch Immunol Ther Exp 48:547
  217. •Weber-Dabrowska, B. et al. (2000) ‘Effective phage therapy is associated with normalization of cytokine production by blood cell cultures‘ Arch Immunol Ther Exp 48:31-37
  218. •Weber-Dabrowska, B. et al. (2001) ‘Bacteriophage therapy for infections in cancer patients‘ Clin Appl Immunol Rev 1:131
  219. •Weber-Dabrowska, B. et al. (2003) ‘Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man‘ Transplant Proc 35:1385-6
  220. •Wegrzyn, G. and Thomas, M.S. (2002) ‘Modulation of the susceptibility of intestinal bacteria to bacteriophages in response to Ag43 phase variation -- a hypothesis‘ Med Sci Monit 8:HY15-8
  221. •Weitz, J.S. et al. (2005) ‘Coevolutionary arms races between bacteria and bacteriophage‘ PNAS 102:9535-40
  222. •Westwater, C. et al. (2003) ‘Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections’ Antimicrob Agent Chemother 47:1301–7
  223. •Will, Q.F. et al. (2005) ‘Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model‘ Antimicrob Agents Chemother 49:1220-1
  224. •Withey, S. et al. (2005) ‘Bacteriophages - potential for application in wastewater treatment processes‘ Sci Total Environ 339:1-18
  225. •Withey, S. et al. (2005) ‘Bacteriophages-potential for application in wastewater treatment processes‘ Sci Total Environ 339:1-18
  226. •Wittig, H.J. et al. (1966) ‘Bacteriophage therapy in infective childhood asthma‘ JAMA 196:435
  227. •Wollman E. (1921) ‘Sur le phenomene de d‘Herelle‘ Compt Rend Soc Biol 84:3
  228. •Wollman, E. and Wollman, E. (1921) ‘Fixite et variabilite des characteres chez les bacteriophage: proprietes antigens‘ Compt Rend Soc Biol 84:332
  229. •Wollman, E. (1935) ‘The phenomenon of Twort d’Herelle and its significance‘ Lancet II:1312-1314
  230. •Wolmer, C. (1952) ‘Über das Vorkommen der Bakteriophagen im Hafen von Tallinn und Emajögi – Estland und über die Verwendung der Staphylophagen, Coliphagen und Typhusphagen für therapeutische Zwecke‘ Zschr Hyg 135:149
  231. •Wolochow, H. et al. (1966) ‘Translocation of microorganisms across the intestinal wall of the rat: effect of microbial size and concentration‘ J Infect Dis 116:523-528
  232. •Wu, L. et al. (2007) ‘Characterization of Extended-Host-Range Pseudo-T-Even Bacteriophage Kpp95 Isolated on Klebsiella pneumoniae‘ Appl Environ Microbiol 73:2532-2540
  233. •Wyckoff, R.W.G. (1949) ‘The nature of bacteriophage‘ Science News (Penguin) 14:60-68
  234. •Xie, H. et al. (2005) ‘Bacteriophage Esc-A is an efficient therapy for Escherichia coli 3-1 caused diarrhea in chickens‘ J Gen Appl Microbiol 51:159-63
  235. •Yen C.H. and Chang K.P.S. (1941) ‘Protective values of various types of Vi-phage on experimental typhoid infection in mice‘ Proc Soc Exp Biol Med 48:243
  236. •Yen C.H. and Chen C.Y. (1940) ‘Urinary excretion of Vi-phage and B. typhosus following phage-inoculation in a typhoid carrier‘ Proc Soc Exp Biol Med
  237. •Yoong P,. et al. (2004) ‘Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium‘ J Bacteriol 186:4808-4812
  238. •Zayteff-Jern, H. und Meleney, F.L. (1941) ‘Studies in bacteriophage 6. The effect of sulfapyridine and sulfanilamide on staphylococci and B. coli and their respective bacteriophages‘ J Lab Clin Med 26:1756
  239. •Zdansky, E. (1925) ‘Versuche einer Bakteriophagentherapie bei Coli-Infektionen der abführenden Harnwege‘ Wien Arch Inn Med 11:533-548
  240. •Zemskova, Z.S. and Dorozhkova, I.R. (1991) ‘Pathomorphological evaluation of therapeutic effect of mycophages in tuberculosis‘ Probl Tuberk 11:63-66